Myelodysplastic Syndrome Clinical Trial

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Summary

This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adults (≥18 years) with TCP as defined by BOTH (a) and (b):

a platlet count of ≤ 70,000 platelets/μL blood

ANY ONE OR MORE of (1-3):

confirmed diagnosis of hematologic malignancy, myeloproliferative disorder, myelodysplastic syndrome, or aplasia
undergoing chemotherapy, immunotherapy, radiation therapy or hematopoietic stem cell transplantation
refractory to platelet transfusion defined as two 1-hour CCI of <5,000 on consecutive transfusions of LSP or as defined by local site policy (Sacher, 2003)
WHO Bleeding Score of 2 or 3
Able to provide informed consent directly or through legally authorized representative, and comply with treatment and monitoring
Negative pregnancy test for women of childbearing potential

Exclusion Criteria:

Any disorder or condition related to any venous thrombosis, embolism, or ischemia within the past 3 months
Any disorder or condition related to arterial thrombosis including: ischemia, stroke, MI, or stent placement, within past 6 months
Any valve replacement and/or repair of left atrial appendance occlusion device
Sinusoidal obstruction syndrom (veno-occlusive disease) or cytopkine release syndrome associated with CAR-T cell therapy
Refusal to accept blood products
Liver enzyme blood levels greater than 3× the upper limit of normal (ULN)
Blood creatinine level greater than 3× ULN
Received platelet inhibitor drugs, cyclooxygenase-2 (COX-2) inhibitors, or nonsteroidal anti-inflammatory drugs within 5 days prior to infusion
Currently (at the time of randomization) receiving anticoagulant therapy or antiplatelet therapy. Low dose prophylaxis for line clots is not excluded.
Receipt of any pro-coagulant agents (e.g., DDAVP, recombinant Factor VIIa or prothrombin complex concentrates (PCC)) other than Tranexamic Acid (TXA) or Epsilon Aminocaproic Acid (EACA, Amicar), within 48 hours of first infusion, or with known hypercoagulable state
WHO Bleeding Score of 2 solely due to lumbar puncture, retinal bleeding or GI bleeding or WHO Bleeding Score of 3 solely due to lumbar puncture
Receiving L-asparaginase as part of a current cycle of treatment
Known inherited or acquired bleeding disorder including, but not limited to: acquired storage pool deficiency or paraproteinemia with platelet inhibition
Known inherited or acquired prothrombotic disorders, including antiphospholipid syndrome (Those with lupus anticoagulant or positive antiphospholipid serology without thrombosis are NOT excluded.)
Anuria
On dialysis
Receipt of an investigational drug within 1 month before first infusion, other than for treatment of their underlying disease
Females pregnant or nursing or unwilling to use contraception during and for 30 days after taking the study product (females). Evidence of effective birth control may be used, at the discretion of the physician
Acute or chronic medical disorder that, in the opinion of the Investigator, would impair the ability of the patient to receive or respond to study treatment
Prior participation in this study with successful infusion of the investigational or control product
Currently enrolled in other trials not related to their primary disease process or involving platelet transfusions, platelet growth factors, or other pro-coagulant agents

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

160

Study ID:

NCT04631211

Recruitment Status:

Active, not recruiting

Sponsor:

Cellphire Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
Medstar Georgetown
Washington District of Columbia, 20007, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Rambam Medical Center
Haifa , , Israel
Helse Bergen Haukeland University Hospital
Bergen , , Norway

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

160

Study ID:

NCT04631211

Recruitment Status:

Active, not recruiting

Sponsor:


Cellphire Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.